| Literature DB >> 29983373 |
Shawn Xiong1, Kristina Lorenzen2, Amber L Couzens2, Catherine M Templeton3, Dushyandi Rajendran2, Daniel Y L Mao2, Yu-Chi Juang2, David Chiovitti2, Igor Kurinov4, Sebastian Guettler5, Anne-Claude Gingras6, Frank Sicheri7.
Abstract
The human NDR family kinases control diverse aspects of cell growth, and are regulated through phosphorylation and association with scaffolds such as MOB1. Here, we report the crystal structure of the human NDR1 kinase domain in its non-phosphorylated state, revealing a fully resolved atypically long activation segment that blocks substrate binding and stabilizes a non-productive position of helix αC. Consistent with an auto-inhibitory function, mutations within the activation segment of NDR1 dramatically enhance in vitro kinase activity. Interestingly, NDR1 catalytic activity is further potentiated by MOB1 binding, suggesting that regulation through modulation of the activation segment and by MOB1 binding are mechanistically distinct. Lastly, deleting the auto-inhibitory activation segment of NDR1 causes a marked increase in the association with upstream Hippo pathway components and the Furry scaffold. These findings provide a point of departure for future efforts to explore the cellular functions and the mechanism of NDR1. CrownEntities:
Keywords: FRYL; Furry-like; Hippo tumor suppressor pathway; MOB1; NDR family; X-ray crystallography; kinases; protein kinase
Mesh:
Substances:
Year: 2018 PMID: 29983373 PMCID: PMC6087429 DOI: 10.1016/j.str.2018.05.014
Source DB: PubMed Journal: Structure ISSN: 0969-2126 Impact factor: 5.006
Figure 1Crystal Structure of the Protein Kinase Domain of Human NDR1 in Its Non-Phosphorylated State
(A) Domain architecture of NDR1 kinase highlighting an atypically long activation segment and two phosphoregulatory sites, S281 and T444. Constructs used in this study are highlighted above with black lines.
(B) Ribbon representation of the kinase domain of human NDR1.
Crystallographic Data Collection and Refinement Statistics for Human NDR1KD
| Hs NDR1 + AMP-PNP + Mg2+ | |
|---|---|
| Space group | C2 |
| Molecules per a.u.(RMSD) | 2 (0.051) |
| Wavelength (Å) | 0.9788 |
| Resolution (Å) | 2.2 |
| Rsym (high resolution) | 0.109% (0.491%) |
| Total reflections | 220717 |
| Completeness (high resolution) | 93.7% (87%) |
| Redundancy | 3.5 |
| 8.333 (1.632) | |
| Resolution range (Å) | 50–2.2 |
| Reflections | 47,691 |
| Rfactor/Rfree | 18%/20% |
| Rms deviations | |
| Bonds (Å) | 0.02 |
| Angles (°) | 2.06 |
| Average B-factor (activation segment) | 31.2 (24.6) |
| Ramachandran Data | |
| Most favored | 95.6% |
| Additionally allowed | 4.4% |
| Disallowed | 0% |
Figure 2Structure-Based Sequence Alignment of the Kinase Domain of NDR1
Secondary structure elements are highlighted above the sequence. Degree of conservation highlighted by black (most) to white (least) shading. Species from top to bottom correspond to human (NP_009202.1, NP_055815.1), gorilla (NP_001075071.1), bovine (NP_001075071.1), eagle (XP_010582907.1), zebrafish (NP_998621.1), lizard (XP_003220400.1), turtle (XP_007063535.1), fly (NP_524170.2), worm (NP_508627.5), and budding yeast (NP_014238.3). Red star indicates the previously identified auto-phosphorylation site, Ser281. Blue stars indicate conserved basic residues implicated in the canonical stabilization of the phosphorylated activation segment in a productive conformation. Orange circles indicate serine and threonine residues in the activation segment that may possess phospho-regulation potential. The alignment was generated using CCP4 ALINE (Bond and Schuttelkopf, 2009).
Figure 3Inactive State Features of the Kinase Domain of NDR1
(A) Superimposition of NDR1KD in green and the kinase domain of phosphorylase kinase (PHKKD) in gray bound to the MC peptide substrate in cyan (PDB: 1PHK; Lowe et al., 1997). Top right inset highlights the non-productive outward rotated (≈100°, as indicated by the red arrow) position of helix αC in NDR1KD. Bottom right inset highlights steric clash of the atypically long activation segment of NDR1KD with the MC peptide substrate bound to PHKKD.
(B) Hydrophobic catalytic and regulatory spine representation of NDR1KD.
Figure 4Activation of NDR1 Kinase by MOB1 and/or a Phosphorylated HM Peptide
(A) In vitro kinase assay analysis of wild-type GST-NDR1MBD−KD in the presence and absence of MOB1 activator and/or a phospho-HM peptide in trans. The top two panels show the autoradiograph, and the bottom three panels show protein loading by Coomassie staining.
(B) In vitro auto-phosphorylation analysis of NDR1MBD−KD versus NDR1KD in the presence and absence of MOB1 and/or a phospho-HM peptide in trans. The top panel displays the autoradiograph, and the bottom two panels show protein loading by Coomassie staining.
(C) In vitro auto-phosphorylation and phosphorylation of RAB3IP substrate by NDR1MBD−KD and NDR1KD, in the presence and absence of MOB1 and/or a phospho-HM peptide in trans. The top two panels display autoradiographs for NDR1 auto-phosphorylation and RAB3IP phosphorylation, respectively. The bottom three panels show protein loading by Coomassie staining.
Figure 5Mutational Analysis of the Atypically Long Activation Segment of Human NDR1
See also accompanying Figure S6 for schematic of mutations tested.
(A) In vitro phosphorylation of RAB3IP by wild-type NDR1MBD−KD and the indicated point mutants without (left panel) and with (right panel) the addition of MOB1A. Loading controls are shown by Coomassie staining.
(B) In vitro phosphorylation of the NDR1 substrate RAB3IP by NDR1MBD−KD wild-type and the indicated activation segment deletion mutants without (left panel) and with (right panel) the addition of MOB1A; loading controls are shown by Coomassie staining. Quantification of the autoradiography signals is shown at the bottom (n = 3 independent experiments; error bars, SEM).
Figure 6Conformational and Dynamics Analysis of NDR1 by HDX Mass Spectrometry
HDX-MS was used to evaluate the solvent accessibility of NDR1MBD−KD upon addition of MOB1A or upon the introduction of the 5A activating mutations. Changes to the average deuterium incorporation are highlighted in the structural superimposition of NDR1KD and the Cbk1-Mob2 complex, with appended HDX plots for the indicated regions. For each plot corresponding to the indicated peptide region, HDX time course profiles are shown for NDR1MBD−KD wild-type alone (black), NDR1MBD−KD wild-type with the addition of MOB1A (blue), NDR1MBD−KD 5A alone (green), and NDR1MBD−KD 5A with the addition of MOB1A (purple). HDX plots for peptide elements labeled I–IV represent regions of NDR1 that were most greatly affected by MOB1A binding, as shown by large deviations between blue and black profiles and between purple and green profiles (note: in panel III, the trace for NDR1MBD−KD + MOB1 in blue overlaps with the trace for NDR1MBD−KD5A + MOB1 in pink). HDX plots VI–VIII represent regions of NDR1 most greatly affected by introduction of the 5A mutations, as shown by large deviations between green and black profiles and between purple and blue profiles. HDX plots in panel V represent the DFG motif of NDR1 that was greatly affected by both the addition of MOB1 and the introduction of the 5A mutations. HDX plots VIX–XI are controls representing regions of NDR1 that were not affected by either MOB1 binding or 5A mutations. HDX plots in panels IX, X, and XI represent the NDR1 helix αC, a C-terminal region of the kinase domain (denoted C′ tail peptide 1), and helix αF, respectively. Data points represent means of three replicates; error bars, SEM. WT, wild-type.
Figure 7Michaelis-Menten Kinetic Analysis of the Phosphorylation of the NDR1 Substrate RAB3IP by NDR1MBD−KD
Phosphorylation kinetic analysis of NDR1MBD−KD wild-type (top panel), Y331A mutant (middle panel), and 5A mutant (bottom panel) in the absence of MOB1 (left column) or in the presence of MOB1 (right column). n = 3 experiments done in technical duplicate; error bars, SEM.
Figure 8Analysis of NDR1 Activating Mutations in Cells
(A) TEAD luciferase reporter analysis of NDR1 in Hippo signaling. SW480 cells were co-transfected with the indicated MYC-tagged NDR1 constructs or empty vector, a TEAD luciferase reporter, and a Renilla luciferase control reporter. Luciferase activities were normalized for Renilla luciferase control reporter activities and expressed relative to reporter activities in the absence of NDR1 (vector). The western blot illustrates NDR1 expression levels (β-actin was detected in parallel as a loading control). Asterisks indicate a band seen in the absence of MYC-NDR1 expression and in non-transfected cells, which likely represents endogenous c-MYC. n = 10 experiments (nine in technical duplicate, one singlet); error bars, SEM. Note that transiently expressed MYC-NDR1 Δ38G was consistently expressed at lower levels than other NDR1 constructs.
(B) Affinity purification coupled mass spectrometry analysis of NDR1 interactions in cells. Cells stably expressing BirA∗-FLAG-tagged wild-type NDR1 or NDR1 harboring a Δ38G deletion were induced with tetracycline (total 24 hr) and treated with 150 nM okadaic acid or DMSO for the last 2.5 hr of induction. Affinity purification coupled to mass spectrometry was performed in biological duplicates alongside negative controls, and high-confidence interactions were scored with SAINTexpress and visualized with ProHits-viz (see legend inset). Only interactions with previously reported or suspected regulators are depicted here; the complete list of high-confidence interactions is given in Table S1. OA, okadaic acid.
(C) Validation of the increased interactions between NDR1 Δ38G and FRYL by immunoprecipitation and immunoblotting. FLAG immunoprecipitates or total lysates were incubated with antibodies to FLAG or endogenous FRYL; the negative control consisted of the parental cell line.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Sheep anti-mouse IgG coupled to HRP | GE Healthcare | Cat#NA931; RRID: |
| Donkey anti-rabbit IgG coupled to HRP | GE Healthcare | Cat#NA934; RRID: |
| Mouse anti-FLAG M2 coupled to HRP | Sigma-Aldrich | Cat#A8592-.2MG; RRID: |
| Rabbit anti-FRYL antibody | Bethyl | Cat#A302-643A-M; RRID: |
| Magnetic anti-FLAG M2 beads slurry | Sigma-Aldrich | Cat#M8823; RRID: |
| Mouse anti-MYC 9E10 IgG | Thermo Fisher Scientific | Cat#MA1-81358; RRID: |
| Mouse anti-beta-actin IgG (AC-15) | Abcam | Cat#ab6276; RRID: |
| Goat anti-mouse IgG coupled to DyLight 680 | Thermo Fisher Scientific | Cat#35518; RRID: |
| Agilent | Cat#230280 | |
| Okadaic acid | LC Labs | Cat#O-5857-1mg |
| Protease inhibitor cocktail | Sigma-Aldrich | Cat#P8340 |
| ECL prime Western blotting detection reagent | GE Healthcare | Cat#45002401 |
| Lipofectamine 2000 transfection reagent | Thermo Fisher Scientific | Cat#11668019 |
| 32P-γ-ATP | Perkin Elmer | Cat#BLU002Z250UC |
| Adenosine 5′-(β,γ-imido)triphosphate lithium salt hydrate (AMP-PNP) | Sigma-Aldrich | Cat#A2647-5MG |
| Adenosine 5′-triphosphate (ATP) disodium salt hydrate (ATP) | Sigma-Aldrich | Cat#A26209-10G |
| Dual-Luciferase® Reporter Assay System | Promega | Cat#E1910 |
| Interaction proteomics dataset | ||
| Interaction proteomics dataset | ||
| Protein Data Bank | This study | PDB ID: |
| HEK293 Flp-In T-REx | Invitrogen | Cat#R780-07, RRID:CVCL_U427 |
| SW480 | gift from Chris Lord, ICR; originally obtained from ATCC | Cat#CCL-228 |
| hsNDR1(nco,m12)f | ccgCTCGAGttatctatttcttttccaggtttc | Sigma |
| hsNDR1(i418,stp,kpn)r | catgCCATGGctatgagtaacc | Sigma |
| hsNDR1(k238a)f | cggGGTACCTTAaatatcagattctg | Sigma |
| hsNDR1(k238a)r | ctttgcacaggactggcaaaagcacataggac | Sigma |
| hsNDR1(h241a)f | gtcctatgtgcttttgccagtcctgtgcaaag | Sigma |
| hsNDR1(h241a)r | ggactgaaaaaagcagctaggacagaattttatagg | Sigma |
| hsNDR1(d256a)f | cctataaaattctgtcctagctgcttttttcagtcc | Sigma |
| hsNDR1(d256a)r | cagcctccccagtgctttcactttccag | Sigma |
| hsNDR1(w271c)f | ctggaaagtgaaagcactggggaggctg | Sigma |
| hsNDR1(w271c)r | ggaaagcagaaacctgtaaaagaaatagacg | Sigma |
| See | ||
| pDEST-pcDNA5-BirA∗-FLAG N-term | Vector ID: V8164 (LTRI database) | |
| pDEST-pcDNA5-BirA∗-FLAG N-term-NDR1 and derivatives | this study | N/A |
| pETM-30 | EMBL | |
| pETM-30-Hs NDR1(82-418) and derivatives | this study | N/A |
| pETM-30-Hs NDR1(12-418) and derivatives | this study | N/A |
| 8xGTIIC-luciferase | obtained from Stefano Piccolo via Addgene ( | Cat#34615 |
| ptkRL Renilla luciferase control plasmid | Promega | N/A |
| pDNR-MCS SA | modified from Clontech pDNR Dual ( | N/A |
| pcDNA5 FRT TO-MYC-NDR1 and derivatives | this study | N/A |
| MS data storage and analysis: ProHits | N/A | |
| MS data, Significance Analysis of INTeractome analysis: SAINT | Version exp3.3 | |
| MS data visualization: ProHits-viz | N/A | |
| HDX workbench | Scripps Institute Florida | |
| Coot | ||
| Phenix | ||
| PyMol | Schrodinger | |
| Refmac | ||
| Prism 7 | GraphPad Software, Inc. | |
| LTQ Orbitrap Elite / Velos | Thermo Fisher Scientific | N/A |
| Odyssey® Imaging System | LI-COR | N/A |
| Victor X5 Multilabel Plate Reader | PerkinElmer | N/A |